Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BAX
BAX logo

BAX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
19.180
Open
19.060
VWAP
18.91
Vol
8.49M
Mkt Cap
9.70B
Low
18.770
Amount
160.53M
EV/EBITDA(TTM)
10.93
Total Shares
516.47M
EV
17.36B
EV/OCF(TTM)
13.75
P/S(TTM)
0.87
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others.
Show More

Events Timeline

(ET)
2026-05-28
16:20:00
Major U.S. Averages Advance as Investors Weigh AI Enthusiasm Against Fiscal Outlook
select
2026-05-28
12:00:00
Major Averages Rise at Noon as Investors Weigh AI Enthusiasm and Fiscal Outlook
select
2026-04-30 (ET)
2026-04-30
07:30:00
Sees FY26 Sales Growth Flat to 1%
select
2026-04-30
07:20:00
Baxter Q1 Revenue of $2.7B Exceeds Expectations
select
2026-04-13 (ET)
2026-04-13
09:10:00
Baxter International Showcases New Surgical Solutions
select

News

CNBC
9.5
05-28CNBC
Edwards Lifesciences Corp. Latest Developments
  • Company History and Achievements: Founded in 1960, Edwards Lifesciences made history with the first commercially available artificial heart valve, helping over two million cardiac patients worldwide and achieving a market capitalization of $46 billion, underscoring its significance in the medical device industry.
  • Strong Growth Momentum: In Q1 2026, the company's heart-related therapies business posted approximately 42% year-over-year growth, prompting an upward revision of full-year sales growth guidance to 9%-11%, with projected revenues between $6.5 billion and $6.9 billion, reflecting robust market demand.
  • Improved Profitability: The adjusted EPS guidance was raised to $2.95-$3.05, with operating margins expected at the high end of the 28%-29% range, indicating ongoing enhancements in profitability that bolster investor confidence.
  • Technical and Market Strategy: Edwards' stock consolidated between $75 and $87 over the past six months, and after breaking out, it retraced to the $81 area and rebounded, signaling strong buying interest; the healthy RSI indicates sustained bullish sentiment, making it suitable for momentum investment strategies.
Yahoo Finance
6.5
05-14Yahoo Finance
First Pacific Advisors' Q1 2026 Investment Moves
  • New Additions: In Q1 2026, First Pacific Advisors added 27 stocks, with Baxter International Inc (BAX) being the largest addition at 6,700,925 shares, representing 1.61% of the portfolio and valued at $112.58 million, indicating strong confidence in the healthcare sector.
  • Significant Increases: The firm increased stakes in 22 stocks, notably Liberty Broadband Corp (LBRDK), with an additional 1,973,262 shares, a 73.92% increase impacting the portfolio by 1.42% and valued at $233.52 million, reflecting optimism in the communications industry.
  • Complete Exits: First Pacific Advisors fully exited 5 holdings this quarter, including Charter Communications Inc (CHTR), selling 461,525 shares, resulting in a -1.29% impact on the portfolio, indicating a cautious outlook on this stock.
  • Position Reductions: The firm reduced positions in 23 stocks, with Kinder Morgan Inc (KMI) seeing a significant reduction of 2,743,789 shares, a 67.31% decrease impacting the portfolio by -1.01%, suggesting a reassessment of the energy sector's prospects.
NASDAQ.COM
2.0
05-01NASDAQ.COM
Baxter (BAX) Q1 2026 Earnings Call Transcript
seekingalpha
9.5
04-30seekingalpha
Baxter Exceeds Expectations in Q1 2026 Financials, Shares Rise
  • International Sales Growth: Baxter (BAX) reported $2.7 billion in revenue for Q1 2026, reflecting a ~3% YoY increase that surpassed consensus estimates by $80 million, with international sales contributing $1.3 billion and achieving ~12% YoY growth, indicating strong performance in global markets.
  • U.S. Market Decline: Despite robust international results, U.S. sales fell to $1.4 billion, representing a ~4% YoY decline, a trend that persists even after excluding results from the divested Kidney Care business, highlighting challenges in the domestic market.
  • Adjusted Earnings Per Share: The company's adjusted EPS stood at $0.36, beating estimates by $0.05, although this reflects a ~35% YoY decline primarily due to unfavorable comparisons to the prior year and rising costs related to tariffs and manufacturing, indicating pressure on cost management.
  • Full-Year Outlook Reaffirmed: Baxter reaffirmed its full-year sales growth outlook of 0%-1% and adjusted EPS guidance of $1.85-$2.05, compared to the consensus of 1% growth and $1.91 EPS, demonstrating the company's confidence in its future performance.
NASDAQ.COM
9.5
04-30NASDAQ.COM
Baxter International Reports $15 Million Net Loss in Q1
  • Financial Decline: Baxter International reported a net loss of $15 million in Q1, translating to a loss of $0.03 per share, compared to a net income of $126 million or $0.25 per share in the same quarter last year, indicating a significant decline in profitability.
  • Adjusted Earnings Drop: Excluding items, adjusted income from continuing operations was $0.37 per share, down from $0.62 per share last year, reflecting challenges in cost control and revenue growth.
  • Sales Growth Stagnation: Worldwide net sales grew 3% to $2.70 billion, but organic sales declined by 1%, indicating a growth bottleneck in core operations that may impact future market competitiveness.
  • Cautious Future Outlook: The company projects adjusted earnings from continuing operations for fiscal 2026 to be in the range of $1.85 to $2.05 per share, with sales growth expected to be flat to 1%, reflecting a cautious stance on future performance that could affect investor confidence.
seekingalpha
9.5
04-29seekingalpha
Baxter Scheduled to Announce Q1 Earnings Results
  • Earnings Announcement Date: Baxter (BAX) is set to release its Q1 earnings on April 30 before market open, with a consensus EPS estimate of $0.31, reflecting a significant 43.6% year-over-year decline, which could negatively impact investor sentiment.
  • Revenue Expectations Decline: The anticipated revenue for Q1 is $2.62 billion, down 0.4% year-over-year, indicating pressure on the company amidst competitive market conditions, potentially affecting future investment decisions.
  • Historical Performance Review: Over the past two years, Baxter has beaten EPS and revenue estimates 63% of the time, although recent EPS estimates have seen no upward revisions and seven downward adjustments, raising concerns about its profitability outlook.
  • Analyst Rating Changes: In the last three months, EPS estimates have not seen any upward revisions, while revenue estimates experienced two upward and three downward revisions, suggesting a cautious outlook from analysts regarding Baxter's future performance.
Wall Street analysts forecast BAX stock price to rise
8 Analyst Rating
Wall Street analysts forecast BAX stock price to rise
2 Buy
5 Hold
1 Sell
Hold
Current: 0.000
sliders
Low
15.00
Averages
22.13
High
30.00
Current: 0.000
sliders
Low
15.00
Averages
22.13
High
30.00
Citi
Joanne Wuensch
Neutral -> Sell
downgrade
$19 -> $17
AI Analysis
2026-05-28
New
Reason
Citi
Joanne Wuensch
Price Target
$19 -> $17
AI Analysis
2026-05-28
New
downgrade
Neutral -> Sell
Reason
Citi analyst Joanne Wuensch downgraded Baxter to Sell from Neutral with a price target of $17, down from $19. The company faces a back-half weighted year and is searching for a CFO, the analyst tells investors in a research note. Citi downgrades Baxter to Sell, saying the rest of medical technology valuations are \"dipping into value territory,\" creating better options.
Barclays
NULL
to
Overweight
maintain
$25 -> $27
2026-05-04
Reason
Barclays
Price Target
$25 -> $27
2026-05-04
maintain
NULL
to
Overweight
Reason
Barclays raised the firm's price target on Baxter to $27 from $25 and keeps an Overweight rating on the shares. The comapny surprised investors expecting a guidance cut with a "respectable beat and reiterated outlook," the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for BAX
Unlock Now

Valuation Metrics

The current forward P/E ratio for Baxter International Inc (BAX.N) is 10.17, compared to its 5-year average forward P/E of 14.56. For a more detailed relative valuation and DCF analysis to assess Baxter International Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
14.56
Current PE
10.17
Overvalued PE
18.55
Undervalued PE
10.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
12.20
Current EV/EBITDA
10.57
Overvalued EV/EBITDA
15.35
Undervalued EV/EBITDA
9.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.64
Current PS
0.86
Overvalued PS
2.31
Undervalued PS
0.97

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

which stocks are bearish
Intellectia · 19 candidates
List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceBelowMA20, PriceBelowMA200Month Price Change Pct: <= $-18.00Is Index Component: GSPCMacd: negative
Ticker
Name
Market Cap$
top bottom
LUV logo
LUV
Southwest Airlines Co
20.20B
ULTA logo
ULTA
Ulta Beauty Inc
23.20B
CCL logo
CCL
Carnival Corp
34.68B
IP logo
IP
International Paper Co
19.80B
CPB logo
CPB
Campbell's Co
6.43B
BF.B logo
BF.B
Brown-Forman Corp
10.62B
no which two coins under .01
Intellectia · 347 candidates
Turnover 24h: >= 0Price: $0.00 - $0.01Relative Vol: >= 0Dollar Volume 24h: >= 0
Ticker
Name
Market Cap$
top bottom
PEPE logo
PEPE
Pepe
1.65B
G logo
G
Gravity
56.10M
PUMP logo
PUMP
Pump.fun
716.00M
BONK logo
BONK
Bonk
579.97M
PENGU logo
PENGU
Pudgy Penguins
498.58M
SHIB logo
SHIB
Shiba Inu
3.66B
stocks to short
Intellectia · 43 candidates
Market Cap: >= 5.00BNet Margin: <= -5.00Rsi Category: overbought, moderateMoving Average Relationship: PriceBelowMA200Monthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
SNOW logo
SNOW
Snowflake Inc
60.65B
COIN logo
COIN
Coinbase Global Inc
51.03B
MSTR logo
MSTR
Strategy Inc
45.84B
CRWV logo
CRWV
CoreWeave Inc
41.98B
RBLX logo
RBLX
Roblox Corp
39.90B
TTWO logo
TTWO
Take-Two Interactive Software Inc
38.74B
what's a good day trade today
Intellectia · 119 candidates
Price: $5.00 - $80.00Rsi Category: moderatePrice Change Pct: $4.00 - $20.00Relative Vol: >= 1.80List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
AAL logo
AAL
American Airlines Group Inc
9.40B
SMCI logo
SMCI
Super Micro Computer Inc
17.40B
CMCSA logo
CMCSA
Comcast Corp
107.79B
HPQ logo
HPQ
HP Inc
17.23B
GPK logo
GPK
Graphic Packaging Holding Co
3.60B
JBLU logo
JBLU
JetBlue Airways Corp
2.05B
health care
Intellectia · 10 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Sector: Healthcare, Healthcare Services & EquipmentPe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
UNH logo
UNH
UnitedHealth Group Inc
315.01B
NVS logo
NVS
Novartis AG
278.44B
NVO logo
NVO
Novo Nordisk A/S
263.42B
GILD logo
GILD
Gilead Sciences Inc
160.18B
PFE logo
PFE
Pfizer Inc
147.20B
ELV logo
ELV
Elevance Health Inc
82.20B
what healthcare stocks should i buy
Intellectia · 10 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Sector: Healthcare, Healthcare Services & EquipmentPe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
UNH logo
UNH
UnitedHealth Group Inc
315.01B
NVS logo
NVS
Novartis AG
278.44B
NVO logo
NVO
Novo Nordisk A/S
263.42B
GILD logo
GILD
Gilead Sciences Inc
160.18B
PFE logo
PFE
Pfizer Inc
147.20B
ELV logo
ELV
Elevance Health Inc
82.20B
find similar stocks of hims and hers
Intellectia · 208 candidates
Market Cap: 300.00M - 15.00BPs Ratio: <= 15.00Is Optionable: TrueAnnual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
GH logo
GH
Guardant Health Inc
14.98B
ICLR logo
ICLR
ICON PLC
14.12B
PEN logo
PEN
Penumbra Inc
14.03B
SOLV logo
SOLV
Solventum Corp
13.94B
SNN logo
SNN
Smith & Nephew PLC
13.91B
NBIX logo
NBIX
Neurocrine Biosciences Inc
13.50B
best medical 3 stocks to buy under $20
Intellectia · 22 candidates
Market Cap: >= 500.00MPrice: <= $20.00Beta: LowRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
TAK logo
TAK
Takeda Pharmaceutical Co Ltd
51.17B
HLN logo
HLN
Haleon PLC
45.60B
KVUE logo
KVUE
Kenvue Inc
33.30B
VTRS logo
VTRS
Viatris Inc
15.03B
RDY logo
RDY
Dr Reddy's Laboratories Ltd
11.06B
BAX logo
BAX
Baxter International Inc
10.13B

Whales Holding BAX

P
Pzena Investment Management, Inc.
Holding
BAX
+4.09%
3M Return
A
ARGA Investment Management, LLC
Holding
BAX
-1.32%
3M Return
G
Greenhaven Associates Inc
Holding
BAX
-3.43%
3M Return
T
Thompson, Siegel & Walmsley LLC
Holding
BAX
-4.30%
3M Return
E
Equity Investment Corporation
Holding
BAX
-4.89%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Baxter International Inc (BAX) stock price today?

The current price of BAX is 18.78 USD — it has decreased -2.44

What is Baxter International Inc (BAX)'s business?

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others.

What is the price predicton of BAX Stock?

Wall Street analysts forecast BAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BAX is22.13 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Baxter International Inc (BAX)'s revenue for the last quarter?

Baxter International Inc revenue for the last quarter amounts to 2.70B USD, increased 2.90

What is Baxter International Inc (BAX)'s earnings per share (EPS) for the last quarter?

Baxter International Inc. EPS for the last quarter amounts to -0.03 USD, decreased -112.00

How many employees does Baxter International Inc (BAX). have?

Baxter International Inc (BAX) has 37500 emplpoyees as of May 31 2026.

What is Baxter International Inc (BAX) market cap?

Today BAX has the market capitalization of 9.70B USD.